CN | EN
Neuregen Therapeutics was founded in December 2021，dedicated to developing novel therapeutic products based on its proprietary in vivo cell reprogramming (in situ cell transdifferentiation) technology. The company was founded by a team of neuroscientists, ophthalmologists, CGT experts, and seasoned professionals from the biopharmaceutical industry. 
The current pipeline focuses on therapeutic products for CNS tumors and degenerative blinding ocular diseases, with the plan to steadily expand into broader therapeutic areas of oncology, regenerative medicine and healthy aging.
About Us
Corporate Culture
The course of development
描述

  • 2026

  • 2025

  • 2024

  • 2023

  • 2022

  • 2021

January

• NRG-103 Injection received Investigational New Drug (IND) approval from the NMPA.

• Completed Series A financing.

June

• Phase I clinical trial initiated.

April

• NRG-103 Injection was granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA).

July

• NRG-103 Injection received Investigational New Drug (IND) approval from the U.S. FDA.

December

• Investigator Initiated Trial (IIT) of NRG-103 Injection.

December

• Completed Pre A round financing.

February

• Completed Angel round financing.

December

• Neuregen Therapeutics (Suzhou) Co., Ltd. established.

<
>
Awards and Honors

Since its establishment, Neuregen Therapeutics and its founders has received many awards and recognitions.

Corporate Honors
12>
Founder's Honor
Copyright © 2026Neuregen Therapeutics (Suzhou) Co., Ltd. All rights reserved.
Address: Room E318, Building E, 245Xinjun Circle, Pujiang Town, Minhang District, Shanghai, China
Navigation
描述
Home
About Us
Management Team
Technology Platform
R&D Pipeline
Strategic Cooperation
News Center
Career Development
Contact Us